

مناقشة

Serum Erythropoietin in Adult Lymphoma Patients



Thesis submitted for partial fulfillment of the
Master Degree in Clinical Hematology

Presented by
HAMS MOHAMED KAMAL EL-DEIN
M.B., B.Ch.

56486

616.15
H.M

Under the supervision of

PROF. DR.

OMAR FATHY MOHAMED FATHY

*Professor of Internal Medicine and Head of Hematology Unit
Ain Shams University*

تمت المناقشة
وكتبت الرسالة

د. محمد كرمي مخلوف

PROF. DR.

INAS AHMED ASFOUR

*Professor of Internal Medicine and Clinical Hematology
Ain Shams University*

د. ياسين حجازي
د. إيمان حجازي

DR. NORA MOHAMED EL-KHOLY

*Assistant Professor of Biochemistry
Ain Shams University*

Faculty of Medicine
Ain Shams University
1998





Acknowledgment

I wish to express my gratitude and thanks to Professor Dr. **Omar Fahy Mohamed Fahy**, Professor of Internal Medicine and Head of Hematology Department, Faculty of Medicine, Ain Shams University.

I wish also to express my deepest gratitude and appreciation to Professor Dr. **Inas Asfour**, Professor of Internal Medicine and Clinical Hematology, Faculty of Medicine, Ain Shams University to whom I am greatly indebted for her patience, supervision and valuable suggestions with her advice which allowed me to go through lots of difficulties during this work.

I would like to display my very gratefulness and much regards to Professor Dr. **Noura El-Kholi**, Professor of Biochemistry, Faculty of Medicine, Ain Shams University, for her constructive supervision and her help in achieving the laboratory work.
I am also grateful to Dr. **Maha El-Zmyte**, Lecturer of Internal Medicine, Faculty of Medicine, Ain Shams University, for her support.

Hams Kamal

1998

List of Contents

Page	
1	Introduction and Aim of the Work
3	Review of Literature
3	Chapter I: Malignant Lymphoma
3	Definition and History
4	Epidemiology of Non-Hodgkin lymphoma
9	Classification of Non-Hodgkin lymphoma
16	Lymphoma
16	Clinical Picture of Non-Hodgkin lymphoma
18	Staging of Non-Hodgkin lymphoma
28	Epidemiology of HD
28	Classification of Hodgkin disease
34	Clinical presentation of HD
35	Diagnosis of HD
36	Anemia of chronic disease
43	Chapter II: EPO
49	Biochemistry of EPO
49	Sites of EPO production
51	Regulation of EPO gene
54	Mechanism of action of EPO
58	EPO receptor
61	EPO and disease
65	Recombinant human erythropoietin
72	Subjects and Methods
82	Results
104	Discussion
110	Summary
112	References
151	Appendix
151	Arabic Summary

List of Tables

11	Table (1): Classification of Rappaport
12	Table (2): Modified Rappaport classification
12	Table (3): Working formulation
13	Table (4): Lukes and Collins classification
13	Table (5): Kiel classification
14	Table (6): Update Kiel classification
15	Table (7): REAL classification
19	Table (8): Arbor staging system
20	Table (9): NCI modified staging system
21	Table (10): Murphy's classification
87	Table (11): Comparative study of laboratory data in patients group
88	Table (12): Comparison between serum EPO of the patient and control
88	Table (13): Correlation between serum EPO and laboratory data
89	Table (14): Correlation between serum EPO and other laboratory data
90	Table (15): Comparison between sex and EPO of patient group
91	Table (16): Normal ranges of laboratory investigations
151	Table (17): Clinical laboratory data at time of presentation
152	Table (18): Collective data after 3 cycles of induction
153	Table (19): Clinical data at presentation
154	Table (20): Pathological types and bone marrow examination
156	Table (21): Clinical data after 3 cycles

<i>Table (22): Serum EPO of patients</i>	<i>159</i>
<i>Table (23): Collective data of control group</i>	<i>160</i>

List of figures

81	Figure (1): Standard curve of EPO
92	Figure (2): Comparison between EPO in patient and control
93	Figure (3): Comparison of ESR (B&A)
94	Figure (4): Comparison of retics (B&A)
95	Figure (5): Comparison of lymphocyte (B&A)
96	Figure (6): Comparison of LDH (B&A)
97	Figure (7): Comparison of ALP (B&A)
98	Figure (8): Correlation between EPO (B) and LDH (B)
99	Figure (9): Correlation between EPO (B) and ALP (B)
100	Figure (10): Correlation between EPO (B) and HB (B)
101	Figure (11): Correlation between EPO (B) & Hct (B)
102	Figure (12): Correlation between EPO (A) and Hb (A)
103	Figure (13): Correlation between EPO (A) and Hct (A)

List of Abbreviations

After (A): after 3 cycles
AID: Acquired immunodeficiency syndrome
AILD: Angio-immunoblastic lymphadenopathy with dysproteinemia
ALCL: Anaplastic large cell lymphoma
Before (B): at presentation
CD: cluster of differentiation
CLL: chronic lymphocytic leukemia
Da: Dalton
DLCL: Diffuse large cell lymphoma
EBER: EBV encoded small nuclear RNA
EBV: Epstein Barr virus
EPO: Erythropoietin
EPO-R: EPO receptor
HCL: hairy cell leukemia
HD: Hodgkin disease
HIV: Human immunodeficiency virus
HLA-DR: Human leucocyte antigen DR
H-RS: Human Reed Sternberg cell
HTLV-I: Human T-cell leukemia virus
Ig: immunoglobulin
LD: lymphocyte depletion in HD
LMP2: Latent membrane protein (there is also LMP1)
LP: lymphocyte predominant lymphoplasmaocytic
Lymph%: lymphocyte percentage
M value: mean value
MC: mixed cellularity in HD
MM: multiple myeloma
MOAB: monoclonal antibody

MRI: magnetic resonance image.
NHL: Non-Hodgkin lymphoma
NK: natural killer cell
NS: nodular sclerosis
NS: non-significant
PCR: polymerase chain reaction
Periph.: peripheral
PLL: pro-lymphocytic leukemia
PRCA: pure red cell aplasia
PTCL: peripheral T-cell lymphoma
S: significant
SC: subcutaneous
SD: standard deviation